Want to see IN:GRANULES full AI Analyst Report?
GRANULES Stock Chart & Stats
₹833.65
₹9.25(1.11%)
At close: 4:00 PM EDT
₹833.65
₹9.25(1.11%)
Day’s Range― - ―
52-Week Range₹456.60 - ₹910.00
Previous CloseN/A
Volume917.48K
Average Volume (3M)56.05K
Market Cap
₹212.72B
Enterprise Value₹157.75K
Total Cash (Recent Filing)₹6.26B
Total Debt (Recent Filing)₹18.07B
Price to Earnings (P/E)31.6
Beta0.85
Next Earnings
Nov 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.2%
Share Statistics
EPS (TTM)21.14
Shares Outstanding247,796,920
10 Day Avg. Volume60,875
30 Day Avg. Volume56,048
Financial Highlights & Ratios
PEG Ratio1.38
Price to Book (P/B)2.97
Price to Sales (P/S)2.81
P/FCF Ratio125.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)32.74
Revenue Forecast (FY)₹62.74B
Bulls Say, Bears Say
Bulls Say
Revenue Growth ResumedThe return to revenue growth indicates resilient demand across Granules India's generic medicines and ingredients portfolio. Sustained expansion would improve operating leverage and support investment in manufacturing capacity and regulated-market opportunities.
Vertical IntegrationGranules India's integrated API-to-FDF model can lower input costs, improve supply reliability, and support consistent product quality. Control across the manufacturing chain may strengthen customer relationships and defend competitiveness over multiple operating cycles.
Manageable LeverageConservative and stable leverage gives Granules India financial flexibility to fund capacity, compliance, and product initiatives without excessive balance-sheet strain. Growing equity and assets also provide a stronger base for long-term pharmaceutical manufacturing operations.
Bears Say
Margin PressureLower gross profit amid revenue growth suggests cost headwinds or weaker mix, which can reduce the benefit of scale. If persistent, margin pressure could constrain reinvestment, earnings growth, and the returns available from expanded manufacturing capacity.
Uneven Free Cash FlowVolatile cash conversion indicates that working capital or capital spending is absorbing a meaningful share of reported profits. Persistently weaker free cash flow could limit funding for growth projects and make earnings less reliable as a source of internal capital.
Declining Return On EquityThe decline in return on equity suggests incremental capital is generating lower returns than in earlier periods. This may reflect margin compression, greater asset intensity, or slower utilization gains, reducing the efficiency of future expansion.
Granules India Limited News
GRANULES FAQ
What was Granules India Limited’s price range in the past 12 months?
Granules India Limited lowest stock price was ₹456.60 and its highest was ₹910.00 in the past 12 months.
What is Granules India Limited’s market cap?
Granules India Limited’s market cap is ₹212.72B.
When is Granules India Limited’s upcoming earnings report date?
Granules India Limited’s upcoming earnings report date is Nov 05, 2026 which is in 72 days.
How were Granules India Limited’s earnings last quarter?
Granules India Limited released its earnings results on Jul 21, 2026. The company reported ₹6.95 earnings per share for the quarter, missing the consensus estimate of ₹7.7 by -₹0.75.
Is Granules India Limited overvalued?
According to Wall Street analysts Granules India Limited’s price is currently Overvalued.
Does Granules India Limited pay dividends?
Granules India Limited pays a Annually dividend of ₹1.75 which represents an annual dividend yield of 0.2%. See more information on Granules India Limited dividends here
What is Granules India Limited’s EPS estimate?
Granules India Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Granules India Limited have?
Granules India Limited has 247,796,920 shares outstanding.
What happened to Granules India Limited’s price movement after its last earnings report?
Granules India Limited reported an EPS of ₹6.95 in its last earnings report, missing expectations of ₹7.7. Following the earnings report the stock price went down -0.057%.
Which hedge fund is a major shareholder of Granules India Limited?
Currently, no hedge funds are holding shares in IN:GRANULES
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Granules India Limited
Founded in 1984 and headquartered in Hyderabad, India, Granules India Limited operates as a key player in the pharmaceutical sector. The company is engaged in the manufacturing and global distribution of a diverse range of pharmaceutical products, including active pharmaceutical ingredients (APIs), intermediate compounds for drug formulation, and final dosage forms (FDFs). Its API portfolio addresses various therapeutic categories, such as antiviral medications, treatments for hypertension, antihistamines, anti-infectives, pain relief agents, anticoagulants, anti-fibrinolytic drugs, and platelet inhibitors. Additionally, Granules produces a variety of FDFs, encompassing tablets, caplets, and press-fit capsules, which are supplied in bulk, blister packs, and bottles. The firm also develops specialized products for oncology. Granules India Limited maintains a broad international presence, with its products reaching markets across India, North America, Europe, Latin America, Africa, and the Middle East.
Technical Analysis
Aurobindo Pharma Ltd
―
Glenmark Life Sciences Limited
―
Jubilant Pharmova Limited
―
Laurus Labs Ltd.
―
Neuland Laboratories Ltd.
―